2,331 Shares in Glaukos Corporation $GKOS Acquired by Ethic Inc.

Ethic Inc. purchased a new position in shares of Glaukos Corporation (NYSE:GKOS) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 2,331 shares of the medical instruments supplier’s stock, valued at approximately $236,000.

Other institutional investors have also added to or reduced their stakes in the company. Bessemer Group Inc. raised its stake in Glaukos by 133.9% during the 1st quarter. Bessemer Group Inc. now owns 276 shares of the medical instruments supplier’s stock worth $27,000 after buying an additional 158 shares during the period. First Horizon Advisors Inc. raised its stake in Glaukos by 72.9% during the 1st quarter. First Horizon Advisors Inc. now owns 377 shares of the medical instruments supplier’s stock worth $37,000 after buying an additional 159 shares during the period. Park Place Capital Corp raised its stake in Glaukos by 68.4% during the 2nd quarter. Park Place Capital Corp now owns 399 shares of the medical instruments supplier’s stock worth $41,000 after buying an additional 162 shares during the period. Bayforest Capital Ltd acquired a new position in Glaukos during the 1st quarter worth approximately $141,000. Finally, Revisor Wealth Management LLC acquired a new position in Glaukos during the 2nd quarter worth approximately $204,000. 99.04% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on GKOS. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Glaukos in a research note on Wednesday, October 8th. JPMorgan Chase & Co. boosted their price objective on Glaukos from $110.00 to $120.00 and gave the stock an “overweight” rating in a report on Thursday. Mizuho set a $130.00 price objective on Glaukos in a report on Thursday, July 31st. Zacks Research lowered Glaukos from a “strong-buy” rating to a “hold” rating in a report on Friday, August 15th. Finally, UBS Group boosted their price objective on Glaukos from $125.00 to $134.00 and gave the stock a “buy” rating in a report on Thursday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Glaukos presently has an average rating of “Moderate Buy” and a consensus price target of $118.62.

Glaukos Stock Performance

GKOS stock opened at $88.21 on Friday. The firm has a market cap of $5.06 billion, a PE ratio of -57.28 and a beta of 0.76. The company has a quick ratio of 4.69, a current ratio of 5.51 and a debt-to-equity ratio of 0.09. The business has a 50 day moving average of $85.55 and a 200-day moving average of $91.57. Glaukos Corporation has a 12-month low of $73.16 and a 12-month high of $163.71.

Glaukos (NYSE:GKOS) last released its earnings results on Wednesday, October 29th. The medical instruments supplier reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.11. The company had revenue of $133.54 million during the quarter, compared to analyst estimates of $122.55 million. Glaukos had a negative return on equity of 7.53% and a negative net margin of 18.65%.Glaukos’s quarterly revenue was up 38.1% on a year-over-year basis. During the same period in the prior year, the company posted ($0.28) earnings per share. Glaukos has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that Glaukos Corporation will post -1.08 earnings per share for the current year.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.